Topical imiquimod yields systemic effects due to unintended oral uptake.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Grine, LyndaSteeland, Sophie
Van Ryckeghem, Sara
Ballegeer, Marlies
Lienenklaus, Stefan
Weiss, Siegfried
Sanders, Niek N
Vandenbroucke, Roosmarijn E
Libert, Claude
Issue Date
2016
Metadata
Show full item recordAbstract
Repetitive application of topical imiquimod is used as an experimental model for the induction of psoriasiform skin lesions in mice. The model is characterized by several inflammatory processes, including cytokine production both locally and systemically, cellular infiltration, and splenomegaly. To investigate the production of type I interferons in response to imiquimod-containing Aldara cream, IFNβ-luciferase reporter mice were imaged in vivo and ex vivo. Type I interferons were found to be produced in the skin, but also in the intestinal system caused by unintended ingestion of imiquimod by the mice. Through the use of Elizabethan collars to prevent ingestion, these effects, including psoriasiform lesions were nearly completely prevented. Our findings reveal that topical treatment with Aldara induces a psoriasiform skin inflammation, but that its mode of action depends on ingestion of the chemical, which leads to systemic responses and affects local inflammation. Therefore, potential ingestion of topical treatments during experimental procedures should be taken into account during assessment of cutaneous inflammatory parameters in skin disease models.Citation
Topical imiquimod yields systemic effects due to unintended oral uptake. 2016, 6:20134 Sci RepAffiliation
Helmholtz Centre for infection research, Inhoffenstr. 7, 38124 Braunschweig, Germany.Journal
Scientific reportsPubMed ID
26818707Type
ArticleLanguage
enISSN
2045-2322ae974a485f413a2113503eed53cd6c53
10.1038/srep20134
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/
Related articles
- IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice.
- Authors: Van Belle AB, de Heusch M, Lemaire MM, Hendrickx E, Warnier G, Dunussi-Joannopoulos K, Fouser LA, Renauld JC, Dumoutier L
- Issue date: 2012 Jan 1
- Psoriasiform eruption and oral ulcerations as adverse effects of topical 5% imiquimod treatment in children: a report of four cases.
- Authors: Smith WA, Siegel D, Lyon VB, Holland KE
- Issue date: 2013 Nov-Dec
- Aldara-induced psoriasis-like skin inflammation: isolation and characterization of cutaneous dendritic cells and innate lymphocytes.
- Authors: Wohn CT, Pantelyushin S, Ober-Blöbaum JL, Clausen BE
- Issue date: 2014
- Psoriasis induced by topical imiquimod.
- Authors: Wu JK, Siller G, Strutton G
- Issue date: 2004 Feb
- A Localized Aldara (5% Imiquimod)-Induced Psoriasiform Dermatitis Model in Mice Using Finn Chambers.
- Authors: Horváth S, Kemény Á, Pintér E, Gyulai R
- Issue date: 2020 Sep